Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CR4A:GR

410.9800 EUR 0.9500 0.23%

As of 13:52:34 ET on 02/27/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CR4A)

Open: 416.0600 High - Low: 418.0600 - 410.9800 Primary Exchange: Berlin
Volume: 0 52-Week Range: 201.6000 - 418.0600 Beta vs NBI: 0.9640

ETF Chart for CR4A

No chart data available.
  • CR4A:GR 416.0260
  • 1D
  • 1M
  • 1Y
411.9300
Interactive CR4A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CR4A

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 2001-11-06 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CR4A

NAV -
Assets (M) (on 2015-02-26) 251.4895
Shares out (M) 0.47
Market Cap (M) 191.63
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for CR4A

No dividends reported

Performance for CR4A

1-Month +3.33% 1-Year +51.18%
3-Month +24.68% 3-Year +48.53%
Year To Date +19.12% 5-Year +34.46%
Expense Ratio -

Top Fund Holdings for CR4A

Filing Date: 12/31/2014
Name Position Value % of Total
Amgen Inc 105,973 16,880,439 7.501%
Celgene Corp 150,276 16,809,873 7.470%
Gilead Sciences Inc 162,484 15,315,742 6.806%
Biogen Idec Inc 44,745 15,188,690 6.749%
Regeneron Pharmaceuticals Inc 27,000 11,076,750 4.922%
Vertex Pharmaceuticals Inc 90,000 10,692,000 4.751%
Incyte Corp 145,000 10,600,950 4.711%
BioMarin Pharmaceutical Inc 115,444 10,436,138 4.637%
Alexion Pharmaceuticals Inc 52,752 9,760,703 4.337%
Medivation Inc 80,000 7,968,800 3.541%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil